Included in this section:|
Bridge Study: Bridging Anticoagulation : The Bridge study will determine whether a bridging blood thinner called dalteparin is helpful or harmful for people with atrial fibrillation who stop taking warfarin in preparation for surgery or another procedure.
CABANA: Comparing Catheter Ablation & Drug Therapy for Atrial Fibrillation: The CABANA trial will explore the appropriate roles for medical and ablative intervention for atrial fibrillation (AF).
EVEREST II Clinical Trial: The purpose of this study is to continue evaluation and monitoring of the safety and effectiveness of an investigational device that repairs the mitral valve.
GORE Reduce Study: Goal of trial is to demonstrate that patent foramen ovale closure with the GORE HELEX Septal Occluder plus antiplatelet medical management is safe and effective and reduces risk of recurrent stroke or imaging-confirmed transient ischemic attack when compared to antiplatelet medical management alone.
IxCELL-DCM: Stem Cell Study: The purpose of the ixCELL-DCM Study is to evaluate the safety and efficacy of using stem cells from the patient's own bone marrow to treat chronic congestive heart failure due to ischemic dilated cardiomyopathy.
Moderate or Severe Pulmonary Regurgitation Study: The purpose of this study is to assess the safety and effectiveness of pulmonic THV implantation in subjects with dysfunctional RVOT conduit requiring treatment for moderate or severe pulmonary regurgitation and/or right ventricular outflow tract conduit obstruction by transthoracic echocardiogram.
The PARTNER II Trial: The purpose of this trial is to determine the safety and effectiveness of an aortic valve device in patients with critical narrowing of the aortic valve that are deemed high risk and are not surgical candidates.
Vitamin D and Omega-3 Fatty Acids Primary Prevention Study: The purpose of this five-year study is to determine the role of vitamin D, marine omega-3 fatty acids, or the combination of vitamin D and omega-3 fatty acids, as compared to placebo in the primary prevention of cancer and cardiovascular disease.